PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
144.54%
Some net income increase while VET is negative at -65.41%. John Neff would see a short-term edge over the struggling competitor.
6.81%
D&A growth well above VET's 0.34%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
132.49%
Well above VET's 22.28% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-583.57%
Negative yoy working capital usage while VET is 137.66%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-101.49%
Negative yoy while VET is 80.28%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-155.54%
Both yoy CFO lines are negative, with VET at -4.69%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-25.36%
Both yoy lines negative, with VET at -32.93%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-1.35%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-137.59%
Both yoy lines negative, with VET at -103.07%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-148.60%
Both yoy lines negative, with VET at -410.46%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
4.34%
Debt repayment growth of 4.34% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
300.00%
We slightly raise equity while VET is negative at -96.89%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.